Search

Your search keyword '"Dauba J"' showing total 108 results
Start Over Author "Dauba J"
108 results on '"Dauba J"'

1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Author

Piprot, C, Cals, L, Chaigneau, L, Demarchi, F, N'Guyen, T, Stein, U, Villanueva, C, Bréau, JL, Chouahnia, AK, Saintigny, P, Boué, F, deSaint-Hilaire, P, Guimont, I, Grossat, N, Valenza, B, Lévy, E, Médioni, J, Delbaldo, C, Grenier, J, Pouessel, D, Lavau-Denès, S, Falandry, C, Fournel-Fédérico, C, Freyer, G, Tartas, S, Trillet-Lenoir, V, Bons, F, Auclerc, G, Chièze, S, Raban, N, Tournigand, C, Trager-Maury, S, Bousquet, G, Cuvier, C, Giacchetti, S, Hocini, A, LeMaignan, C, Misset, JL, Avenin, D, Beerblock, C, Gligorov, J, Rivera, P, Roché, H, Bougnoux, P, Hajjaji, N, Capitain, O, Delva, R, Maillart, P, Soulié, P, Bonnefoi, H, Durand, M, Madranges, N, Mauriac, L, Chollet, P, Dillies, AF, Durando, X, Ferrière, JP, Mouret-Reynier, C, Nabholtz, JM, Van Praagh, I, Cottu, P, Diéras, V, Durieux, A, Galotte, M, Girre, V, Henry, S, Iurisci, I, Jouve, M, Laurence, V, Mignot, L, Piperno-Neumann, S, Tresca, P, Coudert, B, Ferrant, E, Mayer, F, Vanneuville, AC, Bonneterre, J, Servent, V, Vanlemmens, L, Vennin, P, Guastalla, JP, Biron, P, Dupuy-Brousseau, L, Lancry, L, Ray-Coquard, I, Rebattu, P, Trédan, O, Extra, JM, Rousseau, F, Tarpin, C, Fabbro, M, Luporsi, E, Uwer, L, Weber, B, Berton-Rigaud, D, Bourbouloux, E, Campone, M, Ferrero, JM, Follana, P, Largillier, R, Mari, V, Costa, B, Curé, H, Eymard, JC, Jovenin, N, Lebrun, D, Meunier, J, Yazbek, G, Gedoin, D, Laguerre, B, Lefeuvre, C, Vauléon, E, Chevrier, A, Guillemet, C, Leheurteur, M, Rigal, O, Tennevet, I, Veyret, C, Brain, E, Guiterrez, M, Mefti-Lacheraf, F, Petit, T, Dalenc, F, Gladieff, L, André, F, Delaloge, S, Domont, J, Ezenfis, J, Spielmann, M, Guillet, P, Boulanger, V, Provençal, J, Stefani, L, Alliot, C, Ré, D, Bellaiche-Miccio, C, Boutan-Laroze, G, Vanica, R, Dion, P, Sadki-Benaoudia, G, Marti, A, Villing, AL, Slama, B, Dutel, JL, Nguyen, S, Saad, R, Arsène, O, Merad-Boudia, Z, Orfeuvre, H, Egreteau, J, Goudier, MJ, Lamy, R, Leduc, B, Sarda, C, Salles, B, Agostini, C, Cauvin, I, Dufresne, A, Mangold, M, Lebouvier-Sadot, S, Audhuy, B, Barats, JC, Cluet-Dennetière, S, Zylberait, D, Netter, G, Gautier-Felizot, L, Cojean-Zelek, I, Plantade, A, Vignot, S, Guardiola, E, Marti, P, deHartingh, I, Diab, R, Dietmann, A, Ruck, S, Portois, C, Oddou-Lagranière, S, Campos-Gazeau, F, Bourcier, A, Priou, F, Geay, JF, Mayeur, D, Gabez, P, ElAmarti, R, Combe, M, Raichon-Patru, P, Amsalhem, P, Dauba, J, Paraiso, D, Guinet, F, Duvert, B, Litor, M, Kara-Slimane, F, Bichoffe, A, Denizon, N, Soyer, P, Morvan, F, Van-Hulst, S, Vincent, L, Alleaume, C, Ibanez-Martin, P, Youssef, A, Tadrist, Z, Carola, E, Pourny, C, Toccanier, JF, Al-Aukla, N, Mahour-Bacha, K, Salvat, J, Nouyrigat, P, Clippe, S, Gouttebel, MC, Vedrine, L, Clavreul, G, Collard, O, Mille, D, Goubely, Y, Hervé, R, Kirscher, S, Plat, F, Delecroix, V, Ligeza-Poisson, V, Coeffic, D, Fric, D, Garnier, C, Leyronnas, C, Kreitman, T, Teissier, E, Martin, P, Rohart deCordoue, S, ElKouri, C, Ramée, JF, Laporte, C, Bernard, O, Altwegg, T, Darut-Jouve, A, Dujols, JP, Darloy, F, Giraud, C, Pottier-Kyndt, V, Achour, N, Drony, S, Moriceau, M, Sarrazin, C, Legueul, JC, Mandet, J, Besson, D, Hardy-Bessard, AC, Cretin, J, Houyau, P, Achille, E, Genêt, D, Thévenot, H, Moran-Ribon, A, Pavlovitch, JM, Ardisson, P, Moullet, I, Couderc, B, Fichet, V, Burki, F, Auliard, A, Levaché, CB, Cailleux, P, Schaeffer, F, Albin, N, Sévin-Robiche, D, Domas, J, Ellis, S, Montcuquet, P, Baumont, GA, Bégue, M, Gréget, S, Ratoanina, JL, Vanoli, A, Bielsa, C, Bonichon-Lamichhane, M, Jaubert, D, Laharie-Mineur, H, Alcaraz, L, Legouffe, E, Bourgeois, H, Cartron, G, Denis, F, Dupuis, O, Ganem, G, Roche-Forestier, S, Delzenne, L, Chirat, E, Baticle, JL, Béguier, E, Jacquot, S, Janssen, E, Lauché, H, LeRol, A, Chantelard, JP, L'Helgoualc'h, GA, Antoine, EC, Kanoui, A, Llory, JF, Vannetzel, JM, Vignoud, J, Bruna, C, Facchini, T, Moutel-Corviole, K, Voloch, A, Ghoul, A, Loiseau, D, Barbet, N, Dohollou, N, Yakendji, K, Pivot, Xavier, Romieu, Gilles, Debled, Marc, Pierga, Jean-Yves, Kerbrat, Pierre, Bachelot, Thomas, Lortholary, Alain, Espié, Marc, Fumoleau, Pierre, Serin, Daniel, Jacquin, Jean-Philippe, Jouannaud, Christelle, Rios, Maria, Abadie-Lacourtoisie, Sophie, Venat-Bouvet, Laurence, Cany, Laurent, Catala, Stéphanie, Khayat, David, Gambotti, Laetitia, Pauporté, Iris, Faure-Mercier, Celine, Paget-Bailly, Sophie, Henriques, Julie, and Grouin, Jean Marie

Published
2019
Full Text
View/download PDF

2. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

3. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Author

Trédan, O., Follana, P., Moullet, I., Cropet, C., Trager-Maury, S., Dauba, J., Lavau-Denes, S., Diéras, V., Béal-Ardisson, D., Gouttebel, M., Orfeuvre, H., Stefani, L., Jouannaud, C., Bürki, F., Petit, T., Guardiola, E., Becuwe, C., Blot, E., Pujade-Lauraine, E., and Bachelot, T.

Published
2016
Full Text
View/download PDF

4. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Author

Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F.C., Proudhon, C., MacGrogan, G., Orsini, C., Pulido, M., and Gonçalves, A.

Published
2016
Full Text
View/download PDF

5. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Author

Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C., Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., and Zalcman, G.

Published
2015
Full Text
View/download PDF

7. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†

Author

Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J. P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P. J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., and Raspaud, C.

Published
2015
Full Text
View/download PDF

8. Re: Androgen-Deprivation Therapy Alone or with Docetaxel in Non-Castrate Metastatic Prostate Cancer (GETUG-AFU 15): A Randomised, Open-Label, Phase 3 Trial

Author

Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., Rolland, F., Théodore, C., Deplanque, G., Ferrero, J. M., Pouessel, D., Mourey, L., Beuzeboc, P., Zanetta, S., Habibian, M., Berdah, J. F., Dauba, J., Baciuchka, M., Platini, C., Linassier, C., Labourey, J. L., Machiels, J. P., El Kouri, C., Ravaud, A., Suc, E., Eymard, J. C., Hasbini, A., Bousquet, G., and Soulie, M.

Published
2013
Full Text
View/download PDF

9. Efficacité et tolérance de l’immunothérapie par anti-PD1/PDL1 dans le CBNPC métastatique avec mutation BRAF, HER2 ou MET, amplification MET ou translocation RET. GFPC 01-2018

Author

Guisier, F., primary, Gervais, R., additional, Vinas, F., additional, Doubre, H., additional, Ricordel, C., additional, Ropert, S., additional, Janicot, H., additional, Bernardi, M., additional, Fournel, P., additional, Lamy, R., additional, Perol, M., additional, Dauba, J., additional, Gonzales, G., additional, Falchero, L., additional, Decroisette, C., additional, Assouline, P., additional, Chouaid, C., additional, and Bylicki, O., additional

Published
2020
Full Text
View/download PDF

10. PROGNOSTIC VALUE OF INFLAMMATION-BASED ROUTINE BIOMARKERS IN OLDER PATIENTS WITH CANCER: POOLED ANALYSIS OF THREE PROSPECTIVE COHORTS

Author

Oubaya, N., primary, Soubeyran, P., additional, Reinald, N., additional, Fonck, M., additional, Allain, M., additional, Zebachi, S., additional, Heitz, D., additional, Laurent, M., additional, Rousselot, H., additional, Caillet, P., additional, Dauba, J., additional, Bastuji Garin, S., additional, Albrand, G., additional, Bringuier, M., additional, Rainfray, M., additional, Brain, E., additional, Grellety, T., additional, Paillaud, E., additional, Pélissier, S.Mathoulin, additional, Bellera, C., additional, and Canouï Poitrine, F., additional

Published
2019
Full Text
View/download PDF

11. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Author

Pivot, Xavier, primary, Romieu, Gilles, additional, Debled, Marc, additional, Pierga, Jean-Yves, additional, Kerbrat, Pierre, additional, Bachelot, Thomas, additional, Lortholary, Alain, additional, Espié, Marc, additional, Fumoleau, Pierre, additional, Serin, Daniel, additional, Jacquin, Jean-Philippe, additional, Jouannaud, Christelle, additional, Rios, Maria, additional, Abadie-Lacourtoisie, Sophie, additional, Venat-Bouvet, Laurence, additional, Cany, Laurent, additional, Catala, Stéphanie, additional, Khayat, David, additional, Gambotti, Laetitia, additional, Pauporté, Iris, additional, Faure-Mercier, Celine, additional, Paget-Bailly, Sophie, additional, Henriques, Julie, additional, Grouin, Jean Marie, additional, Piprot, C, additional, Cals, L, additional, Chaigneau, L, additional, Demarchi, F, additional, N'Guyen, T, additional, Stein, U, additional, Villanueva, C, additional, Bréau, JL, additional, Chouahnia, AK, additional, Saintigny, P, additional, Boué, F, additional, deSaint-Hilaire, P, additional, Guimont, I, additional, Grossat, N, additional, Valenza, B, additional, Lévy, E, additional, Médioni, J, additional, Delbaldo, C, additional, Grenier, J, additional, Pouessel, D, additional, Lavau-Denès, S, additional, Falandry, C, additional, Fournel-Fédérico, C, additional, Freyer, G, additional, Tartas, S, additional, Trillet-Lenoir, V, additional, Bons, F, additional, Auclerc, G, additional, Chièze, S, additional, Raban, N, additional, Tournigand, C, additional, Trager-Maury, S, additional, Bousquet, G, additional, Cuvier, C, additional, Giacchetti, S, additional, Hocini, A, additional, LeMaignan, C, additional, Misset, JL, additional, Avenin, D, additional, Beerblock, C, additional, Gligorov, J, additional, Rivera, P, additional, Roché, H, additional, Bougnoux, P, additional, Hajjaji, N, additional, Capitain, O, additional, Delva, R, additional, Maillart, P, additional, Soulié, P, additional, Bonnefoi, H, additional, Durand, M, additional, Madranges, N, additional, Mauriac, L, additional, Chollet, P, additional, Dillies, AF, additional, Durando, X, additional, Ferrière, JP, additional, Mouret-Reynier, C, additional, Nabholtz, JM, additional, Van Praagh, I, additional, Cottu, P, additional, Diéras, V, additional, Durieux, A, additional, Galotte, M, additional, Girre, V, additional, Henry, S, additional, Iurisci, I, additional, Jouve, M, additional, Laurence, V, additional, Mignot, L, additional, Piperno-Neumann, S, additional, Tresca, P, additional, Coudert, B, additional, Ferrant, E, additional, Mayer, F, additional, Vanneuville, AC, additional, Bonneterre, J, additional, Servent, V, additional, Vanlemmens, L, additional, Vennin, P, additional, Guastalla, JP, additional, Biron, P, additional, Dupuy-Brousseau, L, additional, Lancry, L, additional, Ray-Coquard, I, additional, Rebattu, P, additional, Trédan, O, additional, Extra, JM, additional, Rousseau, F, additional, Tarpin, C, additional, Fabbro, M, additional, Luporsi, E, additional, Uwer, L, additional, Weber, B, additional, Berton-Rigaud, D, additional, Bourbouloux, E, additional, Campone, M, additional, Ferrero, JM, additional, Follana, P, additional, Largillier, R, additional, Mari, V, additional, Costa, B, additional, Curé, H, additional, Eymard, JC, additional, Jovenin, N, additional, Lebrun, D, additional, Meunier, J, additional, Yazbek, G, additional, Gedoin, D, additional, Laguerre, B, additional, Lefeuvre, C, additional, Vauléon, E, additional, Chevrier, A, additional, Guillemet, C, additional, Leheurteur, M, additional, Rigal, O, additional, Tennevet, I, additional, Veyret, C, additional, Brain, E, additional, Guiterrez, M, additional, Mefti-Lacheraf, F, additional, Petit, T, additional, Dalenc, F, additional, Gladieff, L, additional, André, F, additional, Delaloge, S, additional, Domont, J, additional, Ezenfis, J, additional, Spielmann, M, additional, Guillet, P, additional, Boulanger, V, additional, Provençal, J, additional, Stefani, L, additional, Alliot, C, additional, Ré, D, additional, Bellaiche-Miccio, C, additional, Boutan-Laroze, G, additional, Vanica, R, additional, Dion, P, additional, Sadki-Benaoudia, G, additional, Marti, A, additional, Villing, AL, additional, Slama, B, additional, Dutel, JL, additional, Nguyen, S, additional, Saad, R, additional, Arsène, O, additional, Merad-Boudia, Z, additional, Orfeuvre, H, additional, Egreteau, J, additional, Goudier, MJ, additional, Lamy, R, additional, Leduc, B, additional, Sarda, C, additional, Salles, B, additional, Agostini, C, additional, Cauvin, I, additional, Dufresne, A, additional, Mangold, M, additional, Lebouvier-Sadot, S, additional, Audhuy, B, additional, Barats, JC, additional, Cluet-Dennetière, S, additional, Zylberait, D, additional, Netter, G, additional, Gautier-Felizot, L, additional, Cojean-Zelek, I, additional, Plantade, A, additional, Vignot, S, additional, Guardiola, E, additional, Marti, P, additional, deHartingh, I, additional, Diab, R, additional, Dietmann, A, additional, Ruck, S, additional, Portois, C, additional, Oddou-Lagranière, S, additional, Campos-Gazeau, F, additional, Bourcier, A, additional, Priou, F, additional, Geay, JF, additional, Mayeur, D, additional, Gabez, P, additional, ElAmarti, R, additional, Combe, M, additional, Raichon-Patru, P, additional, Amsalhem, P, additional, Dauba, J, additional, Paraiso, D, additional, Guinet, F, additional, Duvert, B, additional, Litor, M, additional, Kara-Slimane, F, additional, Bichoffe, A, additional, Denizon, N, additional, Soyer, P, additional, Morvan, F, additional, Van-Hulst, S, additional, Vincent, L, additional, Alleaume, C, additional, Ibanez-Martin, P, additional, Youssef, A, additional, Tadrist, Z, additional, Carola, E, additional, Pourny, C, additional, Toccanier, JF, additional, Al-Aukla, N, additional, Mahour-Bacha, K, additional, Salvat, J, additional, Nouyrigat, P, additional, Clippe, S, additional, Gouttebel, MC, additional, Vedrine, L, additional, Clavreul, G, additional, Collard, O, additional, Mille, D, additional, Goubely, Y, additional, Hervé, R, additional, Kirscher, S, additional, Plat, F, additional, Delecroix, V, additional, Ligeza-Poisson, V, additional, Coeffic, D, additional, Fric, D, additional, Garnier, C, additional, Leyronnas, C, additional, Kreitman, T, additional, Teissier, E, additional, Martin, P, additional, Rohart deCordoue, S, additional, ElKouri, C, additional, Ramée, JF, additional, Laporte, C, additional, Bernard, O, additional, Altwegg, T, additional, Darut-Jouve, A, additional, Dujols, JP, additional, Darloy, F, additional, Giraud, C, additional, Pottier-Kyndt, V, additional, Achour, N, additional, Drony, S, additional, Moriceau, M, additional, Sarrazin, C, additional, Legueul, JC, additional, Mandet, J, additional, Besson, D, additional, Hardy-Bessard, AC, additional, Cretin, J, additional, Houyau, P, additional, Achille, E, additional, Genêt, D, additional, Thévenot, H, additional, Moran-Ribon, A, additional, Pavlovitch, JM, additional, Ardisson, P, additional, Moullet, I, additional, Couderc, B, additional, Fichet, V, additional, Burki, F, additional, Auliard, A, additional, Levaché, CB, additional, Cailleux, P, additional, Schaeffer, F, additional, Albin, N, additional, Sévin-Robiche, D, additional, Domas, J, additional, Ellis, S, additional, Montcuquet, P, additional, Baumont, GA, additional, Bégue, M, additional, Gréget, S, additional, Ratoanina, JL, additional, Vanoli, A, additional, Bielsa, C, additional, Bonichon-Lamichhane, M, additional, Jaubert, D, additional, Laharie-Mineur, H, additional, Alcaraz, L, additional, Legouffe, E, additional, Bourgeois, H, additional, Cartron, G, additional, Denis, F, additional, Dupuis, O, additional, Ganem, G, additional, Roche-Forestier, S, additional, Delzenne, L, additional, Chirat, E, additional, Baticle, JL, additional, Béguier, E, additional, Jacquot, S, additional, Janssen, E, additional, Lauché, H, additional, LeRol, A, additional, Chantelard, JP, additional, L'Helgoualc'h, GA, additional, Antoine, EC, additional, Kanoui, A, additional, Llory, JF, additional, Vannetzel, JM, additional, Vignoud, J, additional, Bruna, C, additional, Facchini, T, additional, Moutel-Corviole, K, additional, Voloch, A, additional, Ghoul, A, additional, Loiseau, D, additional, Barbet, N, additional, Dohollou, N, additional, and Yakendji, K, additional

Published
2019
Full Text
View/download PDF

12. Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase�II study

Author

Chibaudel, Benoist, primary, Bachet, Jean‑Baptiste, additional, Andr�, Thierry, additional, Auby, Dominique, additional, Desram�, J�r�me, additional, Deplanque, Ga�l, additional, Lecaille, C�dric, additional, Louvet, Christophe, additional, Tournigand, Christophe, additional, Lebrun‑Ly, Val�rie, additional, Dauba, J�r�me, additional, Lledo, G�rard, additional, Garcia, Marie‑Line, additional, Dubreuil, Olivier, additional, Hamed, Nabil, additional, Meurisse, Aur�lia, additional, Larsen, Annette, additional, Tijeras‑Raballand, Annemila�, additional, Bonnetain, Franck, additional, and De Gramont, Aimery, additional

Published
2019
Full Text
View/download PDF

13. Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial

Author

Quoix, E., primary, Audigier Valette, C., additional, Lavolé, A., additional, Molinier, O., additional, Westeel, V., additional, Barlesi, F., additional, Le Treut, J., additional, Pichon, E., additional, Dauba, J., additional, Otto, J., additional, Dumont, P., additional, Moreau, L., additional, Madelaine, J., additional, Margery, J., additional, Debieuvre, D., additional, Renault, P.A., additional, Langlais, A., additional, Morin, F., additional, Moro-Sibilot, D., additional, and Souquet, P.-J., additional

Published
2018
Full Text
View/download PDF

14. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Aparicio, Thomas, primary, Ducreux, Michel, additional, Faroux, Roger, additional, Barbier, Emilie, additional, Manfredi, Sylvain, additional, Lecomte, Thierry, additional, Etienne, Pierre-Luc, additional, Bedenne, Laurent, additional, Bennouna, Jaafar, additional, Phelip, Jean-Marc, additional, François, Eric, additional, Michel, Pierre, additional, Legoux, Jean-Louis, additional, Gasmi, Mohamed, additional, Breysacher, Gilles, additional, Rougier, Philippe, additional, De Gramont, Aimery, additional, Lepage, Come, additional, Bouché, Olivier, additional, Seitz, Jean-François, additional, Adenis, A., additional, Alessio, A., additional, Aouakli, A., additional, Azzedine, A., additional, Bedjaoui, A., additional, Bidault, A., additional, Blanchi, A., additional, Botton, A., additional, Cadier-Lagnes, A., additional, Fatisse, A., additional, Gagnaire, A., additional, Gilbert, A., additional, Gueye, A., additional, Hollebecque, A., additional, Lemaire, A., additional, Mahamat, A., additional, Marre, A., additional, Patenotte, A., additional, Rotenberg, A., additional, Roussel, A., additional, Thirot-Bidault, A., additional, Votte, A., additional, Weber, A., additional, Zaanan, A., additional, Dupont-Gossart, A.C., additional, Villing, A.L., additional, Queuniet, A.M., additional, Coudert, B., additional, Denis, B., additional, Garcia, B., additional, Lafforgue, B., additional, Landi, B., additional, Leduc, B., additional, Linot, B., additional, Paillot, B., additional, Rhein, B., additional, Winkfield, B., additional, Barberis, C., additional, Becht, C., additional, Belletier, C., additional, Berger, C., additional, Bineau, C., additional, Borel, C., additional, Brezault, C., additional, Buffet, C., additional, Cornila, C., additional, Couffon, C., additional, De La Fouchardière, C., additional, Giraud, C., additional, Lecaille, C., additional, Lepere, C., additional, Lobry, C., additional, Locher, C., additional, Lombard-Bohas, C., additional, Paoletti, C., additional, Platini, C., additional, Rebischung, C., additional, Sarda, C., additional, Vilain, C., additional, Briac-Levaché, C., additional, Auby, D., additional, Baudet-Klepping, D., additional, Bechade, D., additional, Besson, D., additional, Cleau, D., additional, Festin, D., additional, Gargot, D., additional, Genet, D., additional, Goldfain, D., additional, Luet, D., additional, Malka, D., additional, Peré-Vergé, D., additional, Pillon, D., additional, Sevin-Robiche, D., additional, Smith, D., additional, Soubrane, D., additional, Tougeron, D., additional, Zylberait, D., additional, Carola, E., additional, Cuillerier, E., additional, Dorval Danquechin, E., additional, Echinard, E., additional, Janssen, E., additional, Maillard, E., additional, Mitry, E., additional, Norguet-Monnereau, E., additional, Suc, E., additional, Terrebonne, E., additional, Zrihen, E., additional, Pariente, E.A., additional, Almaric, F., additional, Audemar, F., additional, Bonnetain, F., additional, Desseigne, F., additional, Dewaele, F., additional, Di Fiore, F., additional, Ghiringhelli, F., additional, Husseini, F., additional, Khemissa, F., additional, Kikolski, F., additional, Morvan, F., additional, Petit-Laurent, F., additional, Riot, F., additional, Subtil, F., additional, Zerouala-Boussaha, F., additional, Caroli-Bosc, F.X., additional, Boilleau-Jolimoy, G., additional, Bordes, G., additional, Cavaglione, G., additional, Coulanjon, G., additional, Deplanque, G., additional, Gatineau-Saillant, G., additional, Goujon, G., additional, Medinger, G., additional, Roquin, G., additional, Brixi-Benmansour, H., additional, Castanie, H., additional, Lacroix, H., additional, Maechel, H., additional, Perrier, H., additional, Salloum, H., additional, Senellart, H., additional, Baumgaertner, I., additional, Cumin, I., additional, Graber, I., additional, Trouilloud, I., additional, Boutin, J., additional, Butel, J., additional, Charneau, J., additional, Cretin, J., additional, Dauba, J., additional, Deguiral, J., additional, Egreteau, J., additional, Ezenfis, J., additional, Forestier, J., additional, Goineau, J., additional, Lacourt, J., additional, Lafon, J., additional, Martin, J., additional, Meunier, J., additional, Moreau, J., additional, Provencal, J., additional, Taieb, J., additional, Thaury, J., additional, Tuaillon, J., additional, Vergniol, J., additional, Villand, J., additional, Vincent, J., additional, Volet, J., additional, Bachet, J.B., additional, Barbare, J.C., additional, Souquet, J.C., additional, Grangé, J.D., additional, Dor, J.F., additional, Paitel, J.F., additional, Jouve, J.L., additional, Raoul, J.L., additional, Cheula, J.M., additional, Gornet, J.M., additional, Sabate, J.M., additional, Vantelon, J.M., additional, Vaillant, J.N., additional, Aucouturier, J.P., additional, Barbieux, J.P., additional, Herr, J.P., additional, Lafargue, J.P., additional, Lagasse, J.P., additional, Latrive, J.P., additional, Plachot, J.P., additional, Ramain, J.P., additional, Robin, J.P., additional, Spano, J.P., additional, Douillard, J.Y., additional, Beerblock, K., additional, Bouhier-Leporrier, K., additional, Slimane Fawzi, K., additional, Cany, L., additional, Chone, L., additional, Dahan, L., additional, Gasnault, L., additional, Rob, L., additional, Stefani, L., additional, Wander, L., additional, Baconnier, M., additional, Ben Abdelghani, M., additional, Benchalal, M., additional, Blasquez, M., additional, Carreiro, M., additional, Charbit, M., additional, Combe, M., additional, Duluc, M., additional, Fayolle, M., additional, Gignoux, M., additional, Giovannini, M., additional, Glikmanas, M., additional, Mabro, M., additional, Mignot, M., additional, Mornet, M., additional, Mousseau, M., additional, Mozer, M., additional, Pauwels, M., additional, Pelletier, M., additional, Porneuf, M., additional, Ramdani, M., additional, Schnee, M., additional, Tissot, M., additional, Zawadi, M., additional, Clavero-Fabri, M.C., additional, Gouttebel, M.C., additional, Kaminsky, M.C., additional, Galais, M.P., additional, Abdelli, N., additional, Barrière, N., additional, Bouaria, N., additional, Bouarioua, N., additional, Delas, N., additional, Gérardin, N., additional, Hess-Laurens, N., additional, Stremsdoerfer, N., additional, Berthelet, O., additional, Boulat, O., additional, Capitain, O., additional, Favre, O., additional, Amoyal, P., additional, Bergerault, P., additional, Burtin, P., additional, Cassan, P., additional, Chatrenet, P., additional, Chiappa, P., additional, Claudé, P., additional, Couzigou, P., additional, Feydy, P., additional, Follana, P., additional, Geoffroy, P., additional, Godeau, P., additional, Hammel, P., additional, Laplaige, P., additional, Lehair, P., additional, Martin, P., additional, Novello, P., additional, Pantioni, P., additional, Pienkowski, P., additional, Pouderoux, P., additional, Prost, P., additional, Ruszniewski, P., additional, Souillac, P., additional, Texereau, P., additional, Thévenet, P., additional, Haineaux, P.A., additional, Benoit, R., additional, Coriat, R., additional, Lamy, R., additional, Mackiewicz, R., additional, Beorchia, S., additional, Chaussade, S., additional, Hiret, S., additional, Jacquot, S., additional, Lavau Denes, S., additional, Montembault, S., additional, Nahon, S., additional, Nasca, S., additional, Nguyen, S., additional, Oddou-Lagraniere, S., additional, Pesque-Penaud, S., additional, Fratte, S.P., additional, Chatellier, T., additional, Mansourbakht, T., additional, Morin, T., additional, Walter, T., additional, Boige, V., additional, Bourgeois, V., additional, Derias, V., additional, Guérin-Meyer, V., additional, Hautefeuille, V., additional, Jestin Le Tallec, V., additional, Lorgis, V., additional, Quentin, V., additional, Sebbagh, V., additional, Veuillez, V., additional, Adhoute, X., additional, Coulaud, X., additional, Becouarn, Y., additional, Coscas, Y., additional, Courouble, Y., additional, Le Bricquir, Y., additional, Molin, Y., additional, Rinaldi, Y., additional, Lam, Y.H., additional, and Ladhib, Z., additional

Published
2018
Full Text
View/download PDF

15. Valeur prédictive des biomarqueurs de routine chez les patients âgés atteints de cancer : analyse poolée des cohortes ELCAPA, PHRC Aquitaine et ONCODAGE

Author

Oubaya, N., primary, Soubeyran, P., additional, Reinald, N., additional, Fonck, M., additional, Allain, M., additional, Heitz, D., additional, Laurent, M., additional, Rousselot, H., additional, Caillet, P., additional, Dauba, J., additional, Bastuji-Garin, S., additional, Albrand, G., additional, Bringuier, M., additional, Rainfray, M., additional, Brain, E., additional, Grellety, T., additional, Paillaud, E., additional, Mathoulin-Pélissier, S., additional, Bellera, C., additional, and Canouï-Poitrine, F., additional

Published
2018
Full Text
View/download PDF

16. Abstract P3-12-03: Impact of genetic polymorphisms on plasma levels of tamoxifen and its metabolites and toxicity: 6-months results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295)

Author

White-Koning, M, primary, Arellano, C, additional, Le Morvan, V, additional, Evrard, A, additional, Puzskiel, A, additional, Vachoux, C, additional, Dauba, J, additional, Houyau, P, additional, Poublanc, M, additional, Robert, J, additional, Boyer, J-C, additional, Roché, H, additional, Thomas, F, additional, and Chatelut, E, additional

Published
2018
Full Text
View/download PDF

17. DESIGN OF A PHYSICAL ACTIVITY PROGRAM TO PREVENT FUNCTIONAL DECLINE IN ONCO-GERIATRIC PATIENTS (CAPADOGE): A RANDOMIZED MULTICENTER TRIAL

Author

Adélaïde Doussau, Durrieu J, Périé Jl, Robert B, Maget B, Dauba J, Rieger A, Sophie C. Regueme, Isabelle Bourdel-Marchasson, Bouabdallah K, Zwolakowski, Trager S, Mariette C, and Terrebonne E

Subjects
medicine.medical_specialty, business.industry, media_common.quotation_subject, Cognition, General Medicine, law.invention, Quality of life, Feeling, Randomized controlled trial, Weight loss, law, Intervention (counseling), Multicenter trial, Physical therapy, Medicine, medicine.symptom, business, Balance (ability), media_common
Abstract

Background: Cancer in older patient favours the development of frailty: feeling of exhaustion, loss of weight, decreased muscle strength, slow gait speed, and low physical activity. Objectives: To evaluate the efficacy of adapted physical activity phone advices in limiting the cancer-induced loss of autonomy and frailty phenotype development. Design: Multicenter randomized controlled trial. Setting: Patients (>70y) undergoing curative treatment for cancer (n=400) will be recruited from 12 centres. Intervention: The intervention consists in phoned personalized physical activity advices related to strength, aerobic, balance, proprioception, and flexibility. The contacts are performed twice a month during six months and then monthly until 1 year. The intervention complements the PNNS booklet advices (National Nutritional Health Program). The trial compares "individualized phone advices + PNNS" to "usual care + PNNS". Measurements: Functional, cognitive, clinical and self-reported data are assessed before treatment and at 3, 6, 12, 18, and 24 month follow-up. The primary outcome is the proportion of subjects with a one-year decreased SPPB (Short Physical Performance Battery) score of one point or more, as compared to baseline. The secondary outcomes include quality of life items, rate of hospitalizations, institutionalizations, mortality, Fried phenotype at 1 and 2 years, and the SPPB score at 2 years. Discussion: This large trial will provide clinical data of the effects of an exercise advices intervention in older patients during cancer therapy on function and cognition evolution, and quality of life. The possibilities of minimizing the development of frailty phenotype due to these advices will be explored.

Published
2012
Full Text
View/download PDF

18. Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

Author

Taieb, J., primary, Bonnetain, F., additional, Mineur, L., additional, Bennouna, J., additional, Desrame, J., additional, Faroux, R., additional, Fratte, S., additional, Dauba, J., additional, Vernerey, D., additional, Louvet, C., additional, Lepere, C., additional, Dupuis, O., additional, Becouarn, Y., additional, Mabro, M., additional, Egreteau, J., additional, Bouche, O., additional, Deplanque, G., additional, Ychou, M., additional, de Gramont, A., additional, and André, T., additional

Published
2017
Full Text
View/download PDF

19. Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study

Author

Hardy-Bessard, A.-C., primary, Brocard, F., additional, Leheurteur, M., additional, Melis, A., additional, Dauba, J., additional, Lortholary, A., additional, You, B., additional, Guardiola, E., additional, Grenier, J., additional, Martin-Babau, J., additional, Meunier, J., additional, Follana, P., additional, Savoye, A.-M., additional, Mercier-Blas, A., additional, Marti, A., additional, Despax, R., additional, Barbier, N., additional, Gane, N., additional, Ardisson, P., additional, and Segura-Djezzar, C., additional

Published
2016
Full Text
View/download PDF

20. LBA56 - Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial

Author

Quoix, E., Audigier Valette, C., Lavolé, A., Molinier, O., Westeel, V., Barlesi, F., Le Treut, J., Pichon, E., Dauba, J., Otto, J., Dumont, P., Moreau, L., Madelaine, J., Margery, J., Debieuvre, D., Renault, P.A., Langlais, A., Morin, F., Moro-Sibilot, D., and Souquet, P.-J.

Published
2018
Full Text
View/download PDF

21. 2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study

Author

Fontaniere, C. De La Fouchardiere, primary, Paule, B., additional, Burtin, P, additional, Wallet, J., additional, Tougeron, D., additional, Dourthe, L.M., additional, Etienne, P.L., additional, Mineur, L., additional, Becuwe, C., additional, Maes, P., additional, Dauba, J., additional, Michel, P., additional, Wendling, J.L., additional, Linot, B., additional, Hollebecque, A., additional, Clisant, S., additional, Morere, J.F., additional, Andre, T., additional, Phelip, J.M., additional, and Adenis, A., additional

Published
2015
Full Text
View/download PDF

22. 2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)

Author

Bachet, J.B., primary, Hammel, P., additional, Desrame, J., additional, Chibaudel, B., additional, Debourdeau, P., additional, Dauba, J., additional, Lecomte, T., additional, Seitz, J.F., additional, Tournigand, C., additional, Aparicio, T., additional, Guerin Meyer, V., additional, Taieb, J., additional, Volet, J., additional, Bonnetain, F., additional, and Louvet, C., additional

Published
2015
Full Text
View/download PDF

23. 2090 Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC)

Author

Kramar, A., primary, Paule, B., additional, Burtin, P, additional, Tougeron, D., additional, Desseigne, F., additional, Dourthe, L.M., additional, Wallet, J., additional, Etienne, PL., additional, Mineur, L., additional, Becuwe, C., additional, Maes, P, additional, Dauba, J., additional, Michel, P, additional, Hollebecque, A., additional, Linot, B., additional, Morere, J.F., additional, Fouchardiere, C. De la, additional, Phelip, J.M., additional, Andre, T., additional, and Adenis, A., additional

Published
2015
Full Text
View/download PDF

25. Bevacizumab-Erlotinib As Maintenance Therapy in Metastatic Colorectal Cancer. Final Results of the Gercor Dream Study

Author

Chibaudel, B., primary, Tournigand, C., additional, Samson, B., additional, Scheithauer, W., additional, Mesange, P., additional, Lledo, G., additional, Viret, F., additional, Ramée, J.F., additional, Tubiana-Mathieu, N., additional, Dauba, J., additional, Dupuis, O., additional, Rinaldi, Y., additional, Mabro, M., additional, Aucoin, N., additional, Latreille, J., additional, Bonnetain, F., additional, Louvet, C., additional, Larsen, A.K., additional, André, T., additional, and De Gramont, A., additional

Published
2014
Full Text
View/download PDF

26. Rebecca: a Large Cohort Study of Regorafenib (Reg) in the Real-Life Setting in Patients (Pts) Previously Treated for Metastatic Colorectal Cancer (Mcrc)

Author

Tougeron, D., primary, Desseigne, F., additional, Etienne, P.L., additional, Dourthe, L.M., additional, Mineur, L., additional, Paule, B., additional, Hollebecque, A., additional, Tresch, E., additional, Spaeth, D., additional, Michel, P., additional, Dauba, J., additional, Laplaige, P., additional, Borg, C., additional, Bechade, D., additional, Clisant, S., additional, Phelip, J., additional, De Fouchardiere, C.La, additional, André, T., additional, and Adenis, A., additional

Published
2014
Full Text
View/download PDF

27. A Phase Ii Trial of Abiraterone Acetate Plus Prednisone in Patients with Molecular Apocrine (Her2-Negative) Locally Advanced or Metastatic Breast Cancer: a Ucbg Study

Author

Gonçalves, A., primary, Mailliez, A., additional, Dalenc, F., additional, You, B., additional, L'haridon, T., additional, Leheurteur, M., additional, Tredan, O., additional, Ferrero, J., additional, Del Piano, F., additional, Alliot, C., additional, Lucas, B., additional, Dohollou, N., additional, Cottu, P.H., additional, Dauba, J., additional, De Cremoux, P., additional, Pierga, J., additional, Orsini, C., additional, Pulido, M., additional, Macgrogan, G., additional, and Bonnefoi, H., additional

Published
2014
Full Text
View/download PDF

28. 235P - Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study

Author

Hardy-Bessard, A.-C., Brocard, F., Leheurteur, M., Melis, A., Dauba, J., Lortholary, A., You, B., Guardiola, E., Grenier, J., Martin-Babau, J., Meunier, J., Follana, P., Savoye, A.-M., Mercier-Blas, A., Marti, A., Despax, R., Barbier, N., Gane, N., Ardisson, P., and Segura-Djezzar, C.

Published
2016
Full Text
View/download PDF

29. Abstract P3-13-07: A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study

Author

Ferrero, J-M, primary, Hardy-Bessard, A-C, additional, Capitain, O, additional, Lortholary, A, additional, Salles, B, additional, Follana, P, additional, Herve, R, additional, Deblock, M, additional, Dauba, J, additional, Atlassi, M, additional, and Largillier, R, additional

Published
2013
Full Text
View/download PDF

30. Nutritional Advices in Older Patients at Risk for Malnutrition During Chemotherapy for Cancer: No Effect on Mortality Decreased Rate or Severe Infections. Multicentre Inogad Study

Author

Bourdel-Marchasson, I., primary, Durrieu, J., additional, Doussau, A., additional, Germain, C., additional, Blanc, J.-F., additional, Lahmar, C., additional, Dauba, J., additional, Terrebonne, E., additional, Lecaille, C., additional, Ceccaldi, J., additional, Cany, L., additional, Lavau-Denes, S., additional, Chomy, F., additional, Houede, N., additional, Soubeyran, P., additional, Blanc-Bisson, C., additional, and Fonck, M., additional

Published
2013
Full Text
View/download PDF

31. PP111-SUN THE EFFECTS OF NUTRITIONAL ADVICES IN OLDER PATIENTS AT RISK FOR MALNUTRITION DURING CHEMOTHERAPY FOR CANCER ON THE QUALITY OF INTAKES. MULTICENTRE INOGAD STUDY

Author

Bourdel-Marchasson, I., primary, Durrieu, J., additional, Doussau, A., additional, Germain, C., additional, Blanc, J.-F., additional, Lahmar, C., additional, Dauba, J., additional, Terrebonne, E., additional, Lécaille, C., additional, Ceccaldi, J., additional, Cany, L., additional, Lavau-Denes, S., additional, Houdé, N., additional, Chomy, F., additional, Soubeyran, P., additional, Blanc-Bisson, C., additional, and Fonck, M., additional

Published
2013
Full Text
View/download PDF

32. OP037 NUTRITIONAL ADVICES IN OLDER PATIENTS AT RISK FOR MALNUTRITION DURING CHEMOTHERAPY FOR CANCER: NO EFFECT ON MORTALITY DECREASED RATE OF SEVERE INFECTIONS. MULTICENTRE INOGAD STUDY

Author

Bourdel-Marchasson, I., primary, Blanc-Bisson, C., additional, Doussau, A., additional, Germain, C., additional, Blanc, J.F., additional, Lahmar, C., additional, Dauba, J., additional, Terrebonne, E., additional, Lecaille, C., additional, Ceccaldi, J., additional, Cany, L., additional, Lavau-Denes, S., additional, Houede, N., additional, Chomy, F., additional, Durrieu, J., additional, and Fonck, M., additional

Published
2012
Full Text
View/download PDF

34. DESIGN OF A PHYSICAL ACTIVITY PROGRAM TO PREVENT FUNCTIONAL DECLINE IN ONCO-GERIATRIC PATIENTS (CAPADOGE): A RANDOMIZED MULTICENTER TRIAL

Author

DURRIEU, J., primary, DOUSSAU, A., additional, RIEGER, A., additional, TERREBONNE, E., additional, BOUABDALLAH, K., additional, ZWOLAKOWSKI, M.-D., additional, MAGET, B., additional, DAUBA, J., additional, MARIETTE, C., additional, TRAGER, S., additional, PERIE, J.-L., additional, ROBERT, B., additional, REGUEME, S.C., additional, and BOURDEL-MARCHASSON, I., additional

Published
2012
Full Text
View/download PDF

35. Abstract P6-11-04: Capecitabine Therapy for Locally Advanced or Metastatic Breast Cancer: A Difference between Reported Clinical Trials and Routine Clinical Practice? Results from the ELIXIR Study in Routine Oncology Practice

Author

Dalivoust, P, primary, Debled, M, additional, Asselain, B, additional, Pivot, X, additional, Bobadilla, L, additional, Riviere, A, additional, Gedouin, D, additional, Dauba, J, additional, Marquis, I, additional, and Ray-Coquard, I., additional

Published
2010
Full Text
View/download PDF

38. Weekly paclitaxel (wP) as single agent or in combination with weekly topotecan (wT) or carboplatin (C) in patients with resistant ovarian cancer (ROC): The phase II CARTAXHY randomized trial from GINECO

Author

Gladieff, L., primary, Lortholary, A., additional, Largillier, R., additional, Weber, B., additional, Alexandre, J., additional, Durando, X., additional, Slama, B., additional, Dauba, J., additional, Paraiso, D., additional, and Pujade-Lauraine, E., additional

Published
2009
Full Text
View/download PDF

40. O14 Screening of elderly patient with cancer for early death risk. Results of a prospective multicentric study of 364 patients under chemotherapy

Author

Soubeyran, P., primary, Rainfray, M., additional, Mathoulin-Pelissier, S., additional, Blanc-Bisson, C., additional, Mertens, C., additional, Blanc, J.F., additional, Ravaud, A., additional, Ceccaldi, J., additional, Imbert, Y., additional, Vogt, L., additional, Dauba, J., additional, Pallis, R., additional, Cany, L., additional, Buy, E., additional, Andria, F., additional, Adhoute, X., additional, Chomy, F., additional, and Fonck, M., additional

Published
2006
Full Text
View/download PDF

48. LETTERS.

Author

Wertime, John T., Loveless, Clive, Rogers, Clive, and Dauba, J. L.

Abstract

Several letters to the editor are presented in response to the articles in previous issues including "Connecting Cultures," by Diane Mott, "Taking textiles seriously," and attribution of a North African tie-dyed headscarf on lot 7 in Rippon Boswell's sale to the Morroccan Berbers in the Atlas Mountains.

Published
2006

50. Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients.

Author

Puszkiel A, Dalenc F, Tafzi N, Marquet P, Debled M, Jacot W, Venat-Bouvet L, Ferrer C, Levasseur N, Paulon R, Dauba J, Evrard A, Mauriès V, Filleron T, Chatelut E, Thomas F, and White-Koning M

Subjects
Humans, Female, Middle Aged, Aged, Adult, Chemotherapy, Adjuvant methods, Models, Biological, Prospective Studies, Receptors, Estrogen metabolism, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents therapeutic use, Antineoplastic Agents blood, Antineoplastic Agents administration & dosage, Aged, 80 and over, Letrozole pharmacokinetics, Letrozole administration & dosage, Letrozole therapeutic use, Letrozole blood, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Medication Adherence, Aromatase Inhibitors pharmacokinetics, Aromatase Inhibitors administration & dosage, Aromatase Inhibitors therapeutic use, Aromatase Inhibitors blood
Abstract

Background: Letrozole, an aromatase inhibitor metabolised via CYP2A6 and CYP3A4/5 enzymes, is used as adjuvant therapy for women with hormone receptor (HR)-positive early breast cancer. The objective of this study was to quantify the impact of CYP2A6 genotype on letrozole pharmacokinetics (PK), to identify non-adherent patients using a population approach and explore the possibility of a relationship between non-adherence and early relapse., Methods: Breast cancer patients enrolled in the prospective PHACS study (ClinicalTrials.gov NCT01127295) and treated with adjuvant letrozole 2.5 mg/day were included. Trough letrozole concentrations (C ss,trough ) were measured every 6 months for 3 years by a validated LC-MS/MS method. Concentration-time data were analysed using non-linear mixed effects modelling. Three methods were evaluated for identification of non-adherent subjects using the base PK model., Results: 617 patients contributing 2534 plasma concentrations were included and led to a one-compartment PK model with linear absorption and elimination. Model-based methods identified 28 % of patients as non-adherent based on high fluctuations of their C ss,trough compared to 3 % based on patient declarations. The covariate analysis performed in adherent subjects revealed that CYP2A6 intermediate (IM) and slow metabolisers (SM) had 21 % (CI95 % = 12 - 30 %) and 46 % (CI95 % = 41 - 51 %) lower apparent clearance, respectively, compared to normal and ultrarapid metabolisers (NM+UM). Early relapse (19 patients) was not associated with model-estimated, concentration-based or declared adherence in the total population (p = 0.41, p = 0.37 and p = 0.45, respectively)., Conclusions: These findings will help future investigations focusing on the exposure-efficacy relationship for letrozole in adjuvant setting., Competing Interests: Declaration of competing interest The authors declare no competing interests to declare that are relevant to the content of this article., (Copyright © 2024. Published by Elsevier B.V.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results